This observational study is conducted globally. The aim of the study is to investigate the effectiveness and safety of real-life treatment with Norditropin®. The study population will consist of children and adults who are on treatment with Norditropin® in accordance with normal clinical practice.
Study Type
OBSERVATIONAL
Enrollment
21,249
The effectiveness and safety data collection with the use of Norditropin® in daily clinical practice with adults.
The effectiveness and safety data collection with the use of Norditropin® in daily clinical practice with children.
Novo Nordisk Investigational Site
Prov. de Buenos Aires, Argentina
Novo Nordisk Investigational Site
Brussels, Belgium
Novo Nordisk Investigational Site
Prague, Czechia
Novo Nordisk Investigational Site
Copenhagen S, Denmark
Novo Nordisk Investigational Site
Espoo, Finland
Novo Nordisk Investigational Site
Paris La Défense Cedex, France
Novo Nordisk Investigational Site
Mainz, Germany
Novo Nordisk Investigational Site
Budapest, Hungary
Novo Nordisk Investigational Site
Dublin, Ireland
Novo Nordisk Investigational Site
Kfar Saba, Israel
...and 13 more locations
Effect of Norditropin® treatment on height gain (change in height) in children
Time frame: Study outcomes (study endpoints) will be analysed and reported on annual basis. The mean follow up period for study outcomes is expected to be 5 years in accordance with defined duration of the study.
Effect of Norditropin® treatment on body weight and body composition in adults
Time frame: Study outcomes (study endpoints) will be analysed and reported on annual basis. The mean follow up period for study outcomes is expected to be 5 years in accordance with defined duration of the study.
Effect of Norditropin® treatment body weight, blood biochemistry, bone age, the endocrine system and pubertal development in children
Time frame: Study outcomes (study endpoints) will be analysed and reported on annual basis. The mean follow up period for study outcomes is expected to be 5 years in accordance with defined duration of the study.
Effect of Norditropin® treatment on quality of life, blood biochemistry and the endocrine system in adults
Time frame: Study outcomes (study endpoints) will be analysed and reported on annual basis. The mean follow up period for study outcomes is expected to be 5 years in accordance with defined duration of the study.
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.